Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation
- 28 February 2011
- journal article
- editorial
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 124 (2), 111-114
- https://doi.org/10.1016/j.amjmed.2010.05.007
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Improving Stroke Risk Stratification in Atrial FibrillationAmerican Journal Of Medicine, 2010
- Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practiceThrombosis and Haemostasis, 2010
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR controlThrombosis Research, 2009
- Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patientsThrombosis and Haemostasis, 2009
- Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2008
- Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness dataThrombosis and Haemostasis, 2008
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Low-Dose Aspirin for Prevention of Stroke in Low-Risk Patients With Atrial FibrillationStroke, 2006
- Combined Anticoagulant–Antiplatelet Use and Major Bleeding Events in Elderly Atrial Fibrillation PatientsStroke, 2004